No Data
No Data
Cantor Fitzgerald Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $50
BMO Capital Initiates Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Announces Target Price $50
BMO Capital Initiates Coverage On Rocket Pharmaceuticals With Outperform Rating, Announces Price Target of $50
Rocket Pharmaceuticals Price Target Cut to $36.00/Share From $39.00 by Canaccord Genuity
Rocket Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $36